Intercept Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/05/2024
Intercept Pharmaceuticals Stock Forecast and Price Target
In recent months, five notable analysts have provided yearlong price targets for Intercept Pharmaceuticals, with the average target coming in at $16.13. If it were to be achieved, this would result in a potential downside of approximately -15.11 percent from the most recent closing price in November, 2023. The high end is $18.06, and the low is $14.35. Even if you are not interested in ICPT stock, you should be aware of its competitors and their current standings.
-15.11% Downside
Intercept Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
Intercept Pharmaceuticals's Price has increased by 100.00% In the last year, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $32.25 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$163.79 | Buy/Sell | $178.42 | 12.95% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$311.29 | Buy/Sell | $303.65 | 2.80% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$64.78 | Buy/Sell | $87.82 | 23.49% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$217.51 | Buy/Sell | $299.62 | 32.64% |
Intercept Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Intercept Pharmaceuticals's Revenue has decreased from $312.69M to $285.71M – a 8.63% drop. In the next year, analysts expect Revenue to reach $365.23M – an increase of 27.83%. For the next twelve years, the forecast is for Revenue to grow by 32.82%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$82.44 | Buy/Sell | $111.56 | 33.43% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.76 | Buy/Sell | $77.05 | 46.02% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$76.97 | Buy/Sell | $34.00 | 49.41% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.19 | Buy/Sell | $85.71 | 11.48% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$13.63 | Buy/Sell | $20.42 | 87.09% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.44 | Buy/Sell | $52.00 | 125.04% |
Intercept Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Intercept Pharmaceuticals's EBITDA has decreased by 68.33% In the last two years, from $-213.49M to $-67.62M. In the following year, the 2 analysts surveyed believe that Intercept Pharmaceuticals's EBITDA will decrease by 249.05%, reaching $100.79M. According to professionals, by 2030, Intercept Pharmaceuticals's EBITDA will have decreased by 171.74%, falling down to $48.51M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.40 | Buy/Sell | $17.90 | 92.31% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.05 | Buy/Sell | $33.78 | 75.95% |
Intercept Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Intercept Pharmaceuticals's EBIT has decreased from $-216.61M to $-68.22M – a 68.51% drop! The next year, 12 experts forecast that Intercept Pharmaceuticals's EBIT will decrease by 267.77%, reaching $114.45M. In 2030, professionals predict that Intercept Pharmaceuticals's EBIT will decrease by 183.00%, reaching $56.62M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$42.56 | Buy/Sell | $63.29 | 80.92% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.83 | Buy/Sell | $42.58 | 14.99% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$8.72 | Buy/Sell | $9.94 | 60.55% |
Intercept Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
Intercept Pharmaceuticals's EPS has increased by 100.00% In the last year, going from $-2.46 to $0.00. In the next year, analysts expect EPS to reach $2.15 – an increase of 100.00%. For the next nine years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.54 | Buy/Sell | $40.00 | 28.84% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.74 | Buy/Sell | $25.00 | 108.69% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.81 | Buy/Sell | $6.00 | 17.47% |
Site Navigation
.jpg)